TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Concord Medical Services ( (CCM) ) has issued an update.
On July 7, 2025, Concord Medical Services Holdings Limited announced a supplemental announcement regarding its 2024 annual report, specifically providing additional information on proton therapy services. This follows the listing of its subsidiary, Concord Healthcare Group Co., Ltd., on the Hong Kong Stock Exchange on January 9, 2024, which marks a significant step in enhancing its market presence and accessibility to investors.
Spark’s Take on CCM Stock
According to Spark, TipRanks’ AI Analyst, CCM is a Underperform.
The overall stock score for Concord Medical Services is significantly impacted by its poor financial performance, characterized by declining revenues, high leverage, and negative cash flows. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield. These factors collectively contribute to a low overall stock score, highlighting considerable risk.
To see Spark’s full report on CCM stock, click here.
More about Concord Medical Services
Concord Medical Services Holdings Limited operates in the healthcare industry, focusing primarily on providing advanced medical services such as proton therapy. The company is known for its efforts in expanding healthcare services in China and has a market focus on innovative cancer treatment solutions.
Average Trading Volume: 35,305
Technical Sentiment Signal: Strong Sell
Current Market Cap: $25.18M
For detailed information about CCM stock, go to TipRanks’ Stock Analysis page.